Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of continuous subcutaneous levodopa-carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial.
Espay AJ, Stocchi F, Pahwa R, Albanese A, Ellenbogen A, Ferreira JJ, Giladi N, Gurevich T, Hassin-Baer S, Hernandez-Vara J, Isaacson SH, Kieburtz K, LeWitt PA, Lopez-Manzanares L, Olanow CW, Poewe W, Sarva H, Yardeni T, Adar L, Salin L, Lopes N, Sasson N, Case R, Rascol O; BouNDless Study Group. Espay AJ, et al. Lancet Neurol. 2024 May;23(5):465-476. doi: 10.1016/S1474-4422(24)00052-8. Epub 2024 Mar 15. Lancet Neurol. 2024. PMID: 38499015 Clinical Trial.
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Clinical Trial.
[The power exercises as a risk factor of Parkinson's disease].
Guseva OV, Zhukova NG, Zhukova IA. Guseva OV, et al. Among authors: zhukova ia. Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(12):7-11. doi: 10.17116/jnevro20191191217. Zh Nevrol Psikhiatr Im S S Korsakova. 2019. PMID: 31994508 Russian.
[Parkinson disease and asthenic syndrome].
Zhukova IA, Kolupaeva ES, Zhukova NG. Zhukova IA, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(11):60-63. doi: 10.17116/jnevro201811811160. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PMID: 30585606 Russian.
[Possibilities of retention of work capacity in patients with Parkinson's disease].
Gankina OA, Vasenina EE, Pokhabov DD, Voronov DB, Zhukova IA, Baitimerov AR, Radyuk MA, Bojenkina TV, Razdorskaya VV, Levin OS. Gankina OA, et al. Among authors: zhukova ia. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(6. Vyp. 2):95-98. doi: 10.17116/jnevro201811806295. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PMID: 30346441 Russian.
[Parkinson's disease and glutamate excitotoxicity].
Mironova YS, Zhukova IA, Zhukova NG, Alifirova VM, Izhboldina OP, Latypova AV. Mironova YS, et al. Among authors: zhukova ia. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(6. Vyp. 2):50-54. doi: 10.17116/jnevro201811806250. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PMID: 30346434 Russian.
132 results